Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost

Authors: Camille Bédard, Isabelle Gagnon-Arsenault, Jonathan Boisvert, Samuel Plante, Alexandre K. Dubé, Alicia Pageau, Anna Fijarczyk, Jehoshua Sharma, Laetitia Maroc, Rebecca S. Shapiro, Christian R. Landry

Published: 2024-10-08

DOI: 10.1038/s41564-024-01819-2

Source: Full article

---

Abstract

No abstract found.